Judge Blocks RFK Jr.’s Vaccine Policy Changes, FDA Reviews RSV Shot Safety
A federal judge in Boston has temporarily blocked changes to U.S. Vaccine policies championed by Health and Human Services Secretary Robert F. Kennedy Jr., halting cuts to federally recommended childhood vaccines and addressing concerns over the composition of the Centers for Disease Control and Prevention’s (CDC) vaccine advisory committee. Simultaneously, the Food and Drug Administration (FDA) is reviewing the safety of recently approved monoclonal antibody treatments for Respiratory Syncytial Virus (RSV), raising concerns among public health experts.
Legal Challenge to Vaccine Policies
U.S. District Court Judge Brian Murphy ruled that Secretary Kennedy Jr. Improperly replaced the members of the CDC’s Advisory Committee on Immunization Practices (ACIP), an influential body responsible for making recommendations about vaccine schedules. The decision, made on March 16, 2026, was praised by the American Academy of Pediatrics and other health organizations. “Today’s ruling is a historic and welcome outcome for children, communities, and pediatricians everywhere,” said Dr. Andrew Racine, president of the American Academy of Pediatrics .
The Department of Health and Human Services (HHS) plans to appeal the decision. “HHS looks forward to this judge’s decision being overturned just like his other attempts to keep the Trump administration from governing,” stated HHS spokesman Andrew Nixon . The ruling has as well forced the ACIP to postpone a scheduled meeting where discussions about COVID-19 vaccines and future vaccine policy formulation were planned.
FDA Review of RSV Monoclonal Antibodies
The FDA announced a review in December 2025 of the safety of monoclonal antibody treatments for RSV, a highly contagious virus that can be dangerous for infants . RSV is the most common cause of hospitalization for babies in their first year of life, sometimes requiring ventilation or oxygen support, and can lead to chronic lung disease and asthma .
Two new monoclonal antibody shots have shown approximately 80% effectiveness in preventing severe RSV illness requiring intensive care . As of February 2026, more than half of U.S. Infants had received one of these shots . “They’re very new but they’ve already had great success. The monoclonal antibodies have resulted in major reductions in hospitalizations for babies for RSV infections,” said Dr. Yvonne Maldonado, a pediatric infectious disease specialist at Stanford University .
Concerns and Reassurances
The FDA’s safety review has raised concerns among infectious disease experts, who emphasize the thoroughness of the initial safety evaluations. “These products were already thoroughly reviewed for safety, including by the FDA. The science and the facts will bear out that these are very safe products,” stated Dr. Sean O’Leary, chair of the American Academy of Pediatrics’ infectious disease committee . Dr. O’Leary suspects the review may be linked to Secretary Kennedy Jr.’s broader efforts to undermine immunizations.
However, some individuals have reported adverse reactions to the RSV shots, including fevers, seizures, and, in rare cases, deaths. Brian Hooker, chief medical officer for the Children’s Health Defense, a group critical of vaccine safety, argues that a comprehensive safety review is warranted . Sanofi and Merck, the manufacturers of the shots, maintain their products are safe and that no deaths during clinical studies were linked to the immunization, a conclusion supported by the FDA .
Potential Expansion of Vaccine Injury Compensation
Beyond the RSV vaccine review, another potential change under consideration involves expanding the conditions eligible for compensation through the federal Vaccine Injury Compensation Program. This program provides financial assistance to individuals who experience complications following vaccination. Aaron Siri, an attorney who has challenged vaccine mandates, recently petitioned Secretary Kennedy Jr. To add over 300 conditions to the list of compensable injuries .
Vaccine supporters worry that expanding the program could threaten its financial stability and potentially disrupt the vaccine market by increasing legal liability for manufacturers.